AR071553A1 - Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocaina - Google Patents

Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocaina

Info

Publication number
AR071553A1
AR071553A1 ARP080105737A ARP080105737A AR071553A1 AR 071553 A1 AR071553 A1 AR 071553A1 AR P080105737 A ARP080105737 A AR P080105737A AR P080105737 A ARP080105737 A AR P080105737A AR 071553 A1 AR071553 A1 AR 071553A1
Authority
AR
Argentina
Prior art keywords
disulfiram
dsf
pharmaceutical composition
alcohol
treatment
Prior art date
Application number
ARP080105737A
Other languages
English (en)
Inventor
Carreno Maria Jacqueline Sepulveda
Plessing Rossel Carlos Guillermo Von
Gajardo Fernando Pedro Mella
Original Assignee
Andromaco Lab
Univ Concepcion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andromaco Lab, Univ Concepcion filed Critical Andromaco Lab
Publication of AR071553A1 publication Critical patent/AR071553A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/105—Persulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente esta relacionada con una composicion farmaceutica que comprende un complejo de disulfiram (DSF) con una ciclodextrina (CD), su procedimiento de obtencion, y su uso en el tratamiento de la dependencia de alcohol y cocaína. Reivindicacion 1: Composicion farmacéutica caracterizada porque comprende un complejo de inclusion constituido por disulfiram (DSF) y ciclodextrina (CD), opcionalmente DSF libre o no complejado y uno o más vehículos farmacéuticamente aceptables. Reivindicacion 2: Composicion farmacéutica de acuerdo a la reivindicacion 1 caracterizada porque la CD es hidroxipropil-b-ciclodextrina. Reivindicacion 9: Composicion farmacéutica de acuerdo a la reivindicacion 3 caracterizada porque la proporcion de DSF libre a DSF a la forma de complejo está en el rango de 20:80 hasta 40:60. Reivindicacion 13: Composicion farmacéutica de acuerdo a las reivindicaciones 1 y 7 caracterizada porque el vehículo farmacéuticamente aceptable para formas farmacéuticas líquidas se selecciona de agua, miglyol y oleato de etilo.
ARP080105737A 2007-12-28 2008-12-23 Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocaina AR071553A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CL200703877A CL2007003877A1 (es) 2007-12-28 2007-12-28 Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina.

Publications (1)

Publication Number Publication Date
AR071553A1 true AR071553A1 (es) 2010-06-30

Family

ID=40261622

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080105737A AR071553A1 (es) 2007-12-28 2008-12-23 Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocaina

Country Status (10)

Country Link
US (1) US20110021458A1 (es)
EP (1) EP2238978A1 (es)
KR (1) KR101132954B1 (es)
AR (1) AR071553A1 (es)
BR (1) BRPI0821523A2 (es)
CL (1) CL2007003877A1 (es)
ES (1) ES2364419B1 (es)
MX (1) MX2010007183A (es)
PE (1) PE20091098A1 (es)
WO (1) WO2009083794A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2808630A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
EP2814491A4 (en) * 2012-02-18 2015-08-26 Buck Inst For Res On Aging FORMULATIONS AND METHODS FOR TREATING OR PROPHYLAXIS OF PRE-MCI AND / OR PRE-ALZHEIMER ILLNESSES
EP3311843A1 (en) * 2016-10-13 2018-04-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Compositions comprising dithiocarbamate and cyclodextrin
KR20220010855A (ko) 2020-07-20 2022-01-27 재단법인 제주테크노파크 디설피람 및 그 유도체를 이용한 지방세포의 분화억제 효과를 갖는 비만 개선 및 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678809A (en) * 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
KR20030041577A (ko) * 2001-11-20 2003-05-27 디디에스텍주식회사 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물
CN1376463A (zh) 2002-03-29 2002-10-30 沈阳药科大学 双硫伦包合物滴眼剂及其制备方法
DE602004025151D1 (de) 2004-03-10 2010-03-04 Shimoda Biotech Pty Ltd Stabile injizierbare Diclofenac- Zubereitungen
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions

Also Published As

Publication number Publication date
KR20090073026A (ko) 2009-07-02
CL2007003877A1 (es) 2008-06-27
WO2009083794A1 (es) 2009-07-09
ES2364419B1 (es) 2012-09-19
BRPI0821523A2 (pt) 2017-11-14
PE20091098A1 (es) 2009-08-06
EP2238978A1 (en) 2010-10-13
ES2364419A1 (es) 2011-09-02
MX2010007183A (es) 2010-12-17
US20110021458A1 (en) 2011-01-27
KR101132954B1 (ko) 2012-04-24

Similar Documents

Publication Publication Date Title
IT1362675B (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell&#39;istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
CL2010000516A1 (es) Composicion fungicida sin solvente que comprende estrobirulina insoluble en agua dispersado a traves del material portador en forma nano-dispersa teniendo un diametro pico de la forma nano-dispersa menor a 1000 nm; proceso para preparar dicha composicion; uso de dicha composicion para tratar una infestacion (divisional de la sol. 2030-07).
WO2007098128A3 (en) Phenylephrine-containing liquid formulations
TW200700059A (en) A topical composition and its uses
TW200740478A (en) Dispensing device
CO6270297A2 (es) Desodorante basado en propilenglicol/glicerina
AR071553A1 (es) Composiciones farmaceuticas que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina, utiles en el tratamiento de la dependencia de alcohol y cocaina
GT200600264A (es) Modificaciones cristalinas de piraclostrobina
AR062383A1 (es) Uso de polioles para obtener formas polimorfas estables de rifaximina
WO2012075087A3 (en) Silica nanoparticle agent conjugates
CR10937A (es) Inhibidores de cinasa mapk/erk
MY146378A (en) High silicon-content thin film thermosets
AR040093A1 (es) Composicion limpiadora que comprende perlas suspendidas
UY30591A1 (es) Crema para bebidas
ECSP11010762A (es) Composición tópica para el tratamiento de queratosis actínica
ECSP088889A (es) Forma nueva de administración de racecadotril
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CR9853A (es) Compuestos de exemestano (s)-6-metiloxaalquilo y metodos relacionados con su utilizacion
DE602006019670D1 (de) Halbleitervorrichtung und deren Herstellung
DE602004002549D1 (de) Zusammensetzung zur Herstellung eines organischen und isolierenden Filmes sowie der daraus hergestellte Film
AR088157A1 (es) Adsorbente que comprende sobre su superficie una unidad alifatica para la purificacion de moleculas organicas
ATE555028T1 (de) Stützvorrichtung
AR056749A1 (es) Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso
ES2606235T3 (es) Dispositivo de expulsión instalable en un cuerpo de mueble
CL2008000047A1 (es) Compuestos derivados de sulfonamida; procedimiento de preparacion; composicion farmaceutica que contiene a dichos compuestos; y su uso en el tratamiento y profilaxis de aterotrombosis y asma.

Legal Events

Date Code Title Description
FC Refusal
FC Refusal